Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency

Arrowhead Research Corporation ARWR, a targeted therapeutics company, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 13/032,029 entitled, “Compositions for Targeted Delivery of siRNA.” The patent broadly covers compositions, methods, and uses for a new formulation of Arrowhead's Dynamic Polyconjugate (DPC) siRNA delivery platform, where attachment of siRNA and delivery vehicle is not required to produce high-level, efficient knockdown of target genes. The new IP expands the DPC platform and is used in Arrowhead's ARC-520 candidate in development for chronic hepatitis B virus (HBV) infection.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsLegal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!